Inactive Instrument

Celltrion Healthcare Co., Ltd.

A091990

KR7091990002

Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.

April 01, 2022 at 02:40 am EDT

From February 18, 2022 to March 28, 2022, the company has repurchased 630,000 shares, representing 0.4% for KRW 41,546.08 million. With this, the company has completed the repurchase of 630,000 shares, representing 0.4% for KRW 41,546.08 million under the buyback announced on February 18, 2022.

Latest news about Celltrion Healthcare Co., Ltd.

Celltrion's Shares Climb After Merger With Affiliate	Jan. 02	DJ
Celltrion Concludes Merger with Celltrion Healthcare	Dec. 28	MT
Celltrion, Inc. completed the acquisition of a 64.46% stake in Celltrion Healthcare Co., Ltd.	Dec. 27	CI
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on November 9, 2023.	Dec. 18	CI
Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from FTSE All-World Index	Dec. 18	CI
Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from S&P Global BMI Index	Dec. 18	CI
Celltrion Healthcare Co., Ltd.'s Equity Buyback announced on November 9, 2023, has closed with 1,320,000 shares, representing 0.83% for KRW 96,505.56 million.	Dec. 13	CI
S.Korean shares end slightly higher as chipmakers advance; US CPI in focus	Dec. 11	RE
Celltrion Healthcare Co., Ltd. announces an Equity Buyback for 1,320,000 shares.	Nov. 08	CI
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on October 23, 2023.	Nov. 08	CI
Celltrion Healthcare Co., Ltd. authorizes a Buyback Plan.	Nov. 08	CI
Celltrion Healthcare Co., Ltd.'s Equity Buyback announced on October 23, 2023, has closed with 2,440,000 shares, representing 1.52% for KRW 164,432.92 million.	Nov. 06	CI
Celltrion Healthcare to Provide Turkmenistan with Two Anti-Cancer Medications	Nov. 03	MT
Celltrion Healthcare Co., Ltd. announces an Equity Buyback for 2,440,000 shares.	23-10-22	CI
Celltrion Healthcare Co., Ltd. authorizes a Buyback Plan.	23-10-22	CI
Celltrion Healthcare Presents Phase III Data from the LIBERTY-CD and LIBERTY-UC Clinical Trials	23-10-16	CI
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on August 28, 2023.	23-09-13	CI
Celltrion Healthcare Co., Ltd.'s Equity Buyback announced on August 28, 2023 has closed with 690,000 shares, representing 0.43% for KRW 45,263.26 million.	23-09-10	CI
Celltrion Healthcare Co., Ltd. announces an Equity Buyback for 690,000 shares.	23-08-27	CI
Celltrion Healthcare Co., Ltd. authorizes a Buyback Plan.	23-08-27	CI
South Korean Shares Decline on Concerns over US Fed Rate Hike, China Economic Turmoil	23-08-18	MT
South Korean shares post biggest weekly fall in 11 months	23-08-18	RE
Celltrion Discloses Merger Plans with Celltrion HealthCare; Celltrion Shares Jump 5%	23-08-17	MT
South Korean shares set for biggest weekly loss so far in 2023	23-08-17	RE
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on July 6, 2023.	23-07-12	CI

Chart Celltrion Healthcare Co., Ltd.

Duration

Period

More charts

Company Profile

Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn's disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of non-Hodgkin lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.42B
BIOGEN INC.	-18.79%	29.48B
UCB	+57.86%	25.43B
INCYTE CORPORATION	-17.77%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals